Key Stats for Elevance Health Stock
- 52-Week Range: $273 to $428
- Current Price: $346
- Street Mean Target: $382
- Street High Target: $474
- TIKR Model Target (Dec. 2030): $483
What Happened?
Elevance Health (ELV), one of the largest health insurers in the United States and an independent licensee of the Blue Cross and Blue Shield Association, reported first-quarter 2026 results on April 22 that landed well above Wall Street’s expectations.
Adjusted diluted EPS came in at $12.58 against a consensus estimate of $10.82, a beat of more than 16%.
The outperformance had two engines: underlying business strength and approximately $1 per share from non-recurring valuation adjustments within net investment income, with management noting that roughly two-thirds of the core beat reflected genuinely better claims experience.
Elevance Health stock responded accordingly, closing up 5.51% on April 23 to $346.29 after the results, though the stock remains down roughly 19% from its 52-week high of $427.54.
On the back of the Q1 beat, management raised full-year 2026 adjusted diluted EPS guidance to at least $26.75, up from the prior floor of $25.50, and reaffirmed operating cash flow guidance of at least $5.5 billion.
CEO Gail Boudreaux told analysts on the Q1 2026 earnings call that the company is “operating with greater alignment, accountability and clarity across the enterprise,” and that improving claims trends give management “increased confidence in the trajectory of the business.”
The quarter also produced progress on the company’s two core businesses beyond the headline number: Medicare Advantage performance came in ahead of expectations as portfolio repositioning actions took hold, while Medicaid cost trend, though still elevated and running slightly above state rate increases, tracked in line with guidance assumptions.
CarelonRx, Elevance’s integrated pharmacy and health services arm, delivered a strong selling season with two marquee national account wins, and the company reported that clients using integrated medical-pharmacy benefits generated savings of more than $100 per member per month alongside measurable reductions in emergency room visits.
A $935 million accrual tied to a historical CMS risk adjustment data submission dispute was recorded in the quarter and excluded from adjusted results, with management stating that the sanctions are expected not to go into effect if prescribed compliance steps are completed by July 31.
Most critically, management reaffirmed the target of at least 12% adjusted EPS growth in 2027 off a revised 2026 earnings baseline of $25.75, a commitment that frames this year explicitly as a trough and positions 2027 as a step-change recovery.
Wall Street’s Take on ELV Stock
The Q1 beat gives Elevance Health’s bull thesis its first concrete proof point: cost management is translating into results, not just management commentary, and the 2027 reacceleration story now has an operating foundation under it.
ELV’s normalized EPS contracted to $30.29 in 2025 and consensus estimates it falls further to around $26 in 2026, a trough driven by Medicaid margin pressure and Medicare Advantage repositioning costs, before rebounding to around $29 in 2027 as management’s 12% growth target implies.
Thirteen analysts rate Elevance Health stock a buy or outperform against nine holds and zero sells, with a mean price target of $382.19, implying around 10% upside from the current price of $346.29; what Wall Street is specifically waiting for is confirmation that the Medicaid margin floor holds and that Carelon’s risk-based expansion begins contributing to segment earnings in the back half of 2026.
Priced at roughly 13x 2026 trough EPS while management has committed to at least 12% normalized EPS growth in 2027 off a $25.75 baseline, Elevance Health stock appears undervalued against a recovery trajectory that the Q1 beat just made materially more credible.
Medicaid margins remain guided at negative 1.75% for the full year, and any deterioration in state rate-setting timelines could compress the 2027 recovery beyond current consensus assumptions.
The Q2 earnings release will be the first real test of whether bronze-plan ACA seasonality deferral flows into claims as modeled, with management guiding Q2 EPS to approximately 23% of revised full-year guidance, or around $6.
What Does the Valuation Model Say?
The TIKR model prices ELV at around $483 under mid-case assumptions, embedding a roughly 3% revenue CAGR and 5.5% EPS CAGR through 2030 — inputs that now look conservative against management’s explicit 12% EPS growth commitment for 2027 off a confirmed $25.75 baseline.
At $346.29, ELV is undervalued: trading at roughly 13x trough-year earnings while the 2027 rebound to around $29 in normalized EPS is backed by a Q1 beat, a guidance raise, and two consecutive quarters of cost trend moderation.
The argument hinges on one thing: whether 2026 is truly the trough, or whether Medicaid margin pressure and CMS overhang extend the compression into next year.
Bull Case
- Q1 adjusted EPS of $12.58 beat consensus by $1.76, with management attributing around $0.30 of that to genuine underlying business favorability, not one-time items
- Medicare Advantage operating margin is tracking toward at least 2% for 2026 after targeted market exits and product repositioning
- CarelonRx logged two marquee national account wins in the 2027 selling season, with integrated medical-pharmacy clients reporting more than $100 in savings per member per month
- Management guided at least 12% EPS growth in 2027 off $25.75, implying normalized EPS of at least around $29, against a current stock price of $346.29
Bear Case
- Medicaid operating margin is guided at negative 1.75% for full-year 2026, with cost trend running above state rate increases in the mid-single-digit range
- The $935 million CMS accrual represents a known exposure, but the resolution process runs through July 31 and the final amount remains uncertain
- Consensus EPS for 2026 sits at around $26, a 12.7% contraction from 2025, and any further guidance revision downward resets the 2027 growth math entirely
- ACA bronze-plan enrollment growth defers claims into the back half of 2026, creating meaningful execution risk if utilization accelerates faster than modeled
Should You Invest in Elevance Health, Inc.?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up ELV stock and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track Elevance Health, Inc. alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Access Professional Tools to Analyze ELV stock on TIKR for Free →
